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Abstract
Parameter estimation problems of mathematical models can often be formulated as nonlinear least
squares problems. Typically these problems are solved numerically using iterative methods. The solution
obtained using these iterative methods usually depends on the choice of the initial iterate. Especially,
when there is no unique minimum to the nonlinear least squares problem, the algorithm finds one of
the solutions near the initial iterate. Hence, the estimated parameter and subsequent analyses using the
estimated parameter depends on the choice of the initial iterate. One way to reduce the analysis bias
due to the choice of the initial iterate is to repeat the algorithm from multiple initial iterates. However,
the procedure can be computationally intensive and is not often implemented in practice. To overcome
this problem, we propose the Cluster Gauss-Newton (CGN) method, an efficient algorithm for finding
multiple possible solutions of nonlinear-least squares problems. The algorithm simultaneously solves the
nonlinear least squares problem from multiple initial iterates. The algorithm iteratively improves the
solutions from these initial iterates similarly to the Gauss-Newton method. However, it uses a global
linear approximation instead of the gradient. The global linear approximations are computed collectively
among all the initial iterates to minimise the computational cost and increase the robustness against
convergence to local minima. We use mathematical models used in pharmaceutical drug development to
demonstrate its use and that the proposed algorithm is computationally more efficient and more robust
against local minima compared to the Levenberg-Marquardt method.
1 Introduction
The parameter estimation of mathematical models often boils down to solving nonlinear least squares prob-
lems. Hence, algorithms for solving nonlinear least squares problems are widely used in many scientific
fields. Most of the algorithms for solving nonlinear least squares problems focus on finding a single solution.
On the other hand, there is very limited methodological development on algorithms for finding multiple
solutions of nonlinear least squares problems when the solution is not unique. Standard methods such as
the Levenberg-Marquardt method can find a solution of a nonlinear least squares problem that does not
have a unique solution. However, the parameter found by the algorithm depends on the choice of the initial
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iterate. To reduce the analysis bias due to the initial iterate used for the algorithm, it is a good practice
to repeatedly use the algorithm with various initial iterates to gain the understanding of the influence of
the initial iterates. On the other hand, due to the computational challenges and cost, it is rarely done in
practice. In this paper, we propose a new computational method for efficiently finding multiple solutions to
nonlinear least squares problems.
Our algorithm development for finding multiple solutions of nonlinear least squar-es problems was moti-
vated by a mathematical model of pharmaceutical drug concentration in a human body called the physio-
logically based pharmacokinetic (PBPK) model. The PBPK model is typically a system of mildly nonlinear
stiff ordinary differential equations (ODEs) with many parameters. This type of mathematical model is
constructed based on the knowledge of the mechanism of how the drug is absorbed, distributed, metabolised
and excreted. Given the complexity of this process and the limitation of the observations we can obtain
from a live human subject, the model parameters cannot be uniquely identified from the observations. The
estimated parameters of the PBPK model are used to simulate the drug concentration of the patient from
whom we are often unable to test the drug on (e.g., children, pregnant person, a person with rare genetic
anomaly) or to predict the experiment that is yet to be run (different amount of drug administration, mul-
tiple drug used at the same time). As the simulated drug concentration is used to predict the safety of
the drug in these different scenarios, it is essential to consider the multiple predictions based on multiple
possible parameters that are estimated from the available observation. A motivating example is presented
in Appendix A.
In [1, 2] we proposed the Cluster Newton (CN) method, which is a computationally efficient method
for obtaining multiple solutions of a system of nonlinear equations. In recent years CN has been used
in the field of pharmaceutical science [19, 6, 3, 15, 10, 11] and shown to be useful for the applications.
For example, [15] used the parameters estimated by CN to predict the drug adverse effect, [11] used the
estimated parameters to predict the outcome of a clinical trial. However, based on these applications of
CN, we observed the necessity for an algorithm to find multiple solutions of a nonlinear least squares
problem. (See Appendix B.)
1.1 Nonlinaer least squares problem of our interest
In this paper, we propose an algorithm for obtaining multiple solutions of a nonlinear least squares problem
min ||f(x)− y∗||2 (1)
that does not have a unique solution, that is to say, there exist x(1) 6= x(2) such that
min ||f(x)− y∗||2 = ||f(x(1))− y∗||2 = ||f(x(2))− y∗||2 . (2)
Here, f is a nonlinear function from Rn to Rm, x(1), x(2) ∈ Rn and y∗ ∈ Rm. The nonlinear function
f can be derived from a mathematical model, the vector x can be regarded as a set of model parameters
which one wishes to estimate, and the vector y∗ can be regarded as a set of observations one wishes to fit
the model to.
In order to make our algorithm as generally applicable as possible and to make it easier to use for a
wide variety of applications, we assume the nonlinear function f to be a ”black-box”. More specifically, we
assume the case where derivatives of f with respect to x are not readily available or the case where f is not
differentiable.
We shall call the following quantity the sum of squares residual (SSR):
||f(x)− y∗|| 22 , (3)
and use it for the quantification of the goodness of x as the approximation of the solution of the least squares
problem (1).
2
1.2 A toy example
To illustrate a least squares problem without a unique solution, we present the following simple toy example.
Let there be an experiment where the observations can be written as a random variable below:
u∗(t) = t+ , (4)
where  is a random variable drawn from the normal distribution of mean 0 standard deviation 0.1 (i.e.,
 ∼ N (0, 0.1) ), and t is the time of the observation. Let us consider the case where we sample five
times e.g., t1 = 1, t2 = 2, t3 = 3, t4 = 4, t5 = 5 and denote these observations as a vector y
∗ =
[u∗(1), u∗(2), u∗(3), u∗(4), u∗(5)]T.
We now consider a case where one has constructed a mathematical model to model this observation as
follows:
u(t; θ1, θ2) =
θ1
θ2
t, (5)
where θ1 and θ2 are model parameters. We can now write the parameter estimation problem from the
observation data y∗ as the following least squares problem
min ||f(x)− y∗||2 (6)
where x = [θ1, θ2]
T and
f(x) = [u(1; θ1, θ2), u(2; θ1, θ2), u(3; θ1, θ2), u(4; θ1, θ2), u(5; θ1, θ2)]
T. (7)
As can be seen trivially from equation (5), this is an over parameterised model and the least squares
problem (6) has infinitely many solutions with α = θ1θ2 where α is a constant close to 1.
For this toy model, deriving the relationship α = θ1θ2 is trivial. Hence, we can analytically reparameterise
the model. However, for a more complex model structure, such a relationship may not be easily expressed
analytically.
2 Method: Algorithm
In this section we describe the proposed algorithm. We first introduce a rough concept using a toy example
in Subsection 2.1 and then introduce the full algorithm in detail in Subsectin 2.2.
2.1 Brief explanation of the algorithm
The aim of the proposed Cluster Gauss-Newton (CGN) algorithm is to efficiently find multiple solutions of
the nonlinear least squares problem (1). We do so by first creating a collection of initial guesses which we call
the ‘cluster’. Then, we move the cluster iteratively using a linear approximation of the nonlinear function
f , similarly to the Gauss-Newton method [4].
The unique idea in our CGN method is that the linear approximation is constructed collectively through-
out the points in the cluster instead of using the Jacobian matrix which approximates the nonlinear function
linearly at a point. By using points in the cluster to construct the linear approximation, we avoid extra
computation of the nonlinear function for approximating the Jacobian matrix. This idea of approximating
the nonlinear function collectively using the points in the cluster was utilised in CN [2]. In the proposed
method, we further improve on the way we do the linear approximation.
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In order to visualise the key differences between these linear approximations, we consider the nonlinear
function f = x2 − 2 cos(10x) and aim to find x that minimises this nonlinear function (cf. Figure 1). The
global minimum of this function is -2 at x = 0. The randomly generated points in the initial cluster is
located at:
x1 = −3.3797853, x2 = −1.1656025, x3 = −0.6145728,
x4 = 1.1540421, x5 = 2.0755468, (8)
as indicated by the red dots. We now compute the linear approximations used to move these points in the
cluster to minimise the function f .
Gradient
For this nonlinear function, the gradient at xi is f
′(xi) = 2x+20 sin(10xi). Practically, when f is a “black
box”, we can approximate the gradient by a finite difference scheme, for example, f ′(xi) ≈ f(xi+)−f(xi) .
Then, the linear approximation at xi can be written as f(x) ≈ f(xi+)−f(xi) (x − xi) + f(xi). Notice that
it requires one extra evaluation of f at xi +  for each xi. This number of extra function evaluation is, in
general, proportional to the dimension of the independent variable of the nonlinear function.
Cluster Newton (CN) method
In CN, we construct one linear approximation for all points in the cluster in the following way.
min
a,b
5∑
i=1
|axi + b− f(xi)| 22 (9)
where a is the slope and b is the intercept of the linear approximation, i.e., f(x) = ax + b. Note that for
CN, we have designed to construct the cluster with more number of points in the cluster than the dimension
of the independent variable of the nonlinear function. Thus equation(9) can be regarded as a least squares
solution of an over determined system of linear equations. Note that we do not need any extra evaluations
of f in order to determine the linear approximation.
Cluster Gauss-Newton (CGN) method (proposed method)
In the proposed method, we construct a linear approximation for each point in the cluster while using
the other points in the cluster to globally approximate the nonlinear function with the linear function. The
influence of another point in the cluster to the linear approximation is weighted according to how close the
point is to the point of approximation, i.e.,
min
a(i)
∑
i 6=j
∣∣∣∣a(i)(xj − xi) + f(xi)− f(xj)(xj − xi)2γ
∣∣∣∣ 2 (10)
where a(i) is the slope of the linear approximation at xi and the linear approximation at xi can be written
as f(x) = a(i)(x − xi) + f(xi), and γ ≥ 0 is a constant. Note that Equation(10) can also be regarded as a
weighted least squares solution of an overdetermined system of linear equations. The weight is motivated
by the fact that we weight the information from the neighbouring points in the cluster more than the ones
further away when constructing the linear approximation. Again, note that we do not require any extra
evaluation of f for obtaining these linear approximations.
We have depicted the linear approximations at each point in the initial cluster in Figure 1. As can be seen,
the regular gradient captures the local behaviour of the nonlinear function. Hence, it is bound to converges
to a local minimum. CN captures the global behaviour of the nonlinear function. Hence, 3 out of 5 points
move towards the global minimum following the linear approximation. However, as we are approximating
the nonlinear function at all points with one linear function, it is not appropriate for some points. The
proposed CGN method, does on the other hand, capture both the global behaviour of the nonlinear function
while having one linear approximation each for each point. Thus, in this example, all points will descend to
the global minimum if the points are moved based on the slope of the linear approximations.
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Figure 1: Schematic comparison of the linear approximations.
2.2 Detailed description of the algorithm
Next, we describe the new algorithm in detail. In this subsection describing the algorithm, we denote a
scalar quantity with a lower case letter (e.g., a, c), a matrix with a capital letter, for example A, or M , and
a column vector by a bold symbol of a lower case letter, (e.g., v, a), unless otherwise specifically stated.
Super script T indicates the transpose. Hence, vT and aT are row vectors.
1) Pre-iteration process
The initial iterate of CGN, a set of vectors {x(0)i }Ni=1 are randomly generated following a uniform
distribution within the lower bound xL and upper bound xU given by the user as the initial estimate of
the plausible location of the solution. That is to say, the value x
(0)
ji is a sample from U(xLj , xUj ), where
x
(0)
ji is the j th element of vector x
(0)
i .
Store the initial set of vectors in a matrix X(0), i.e.,
X(0) = [x
(0)
1 ,x
(0)
2 , · · · ,x(0)N ] (11)
where the super script (0) indicates the initial iterate.
Evaluate the nonlinear function f at each xi and store in matrix Y
(0), i.e.,
Y (0) =
[
f(x
(0)
1 ),f(x
(0)
2 ), · · · ,f(x(0)N )
]
. (12)
If the function f cannot be evaluated at x
(0)
i , then re-sample x
(0)
i until f can be evaluated.
Compute the sum of squares residual vector r(0), i.e.,
r(0) =
[
||f(x(0)1 )− y∗|| 22 , ||f(x(0)2 )− y∗|| 22 , ..., ||f(x(0)N )− y∗|| 22
]T
. (13)
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Fill the regularisation parameter vector λ(0) ∈ RN , with the user-specified initial regularisation
parameter λinit .i.e.,
λ(0) = [λinit, λinit, ..., λinit]
T. (14)
2) Main iteration
Repeat the following procedure until the user specified stopping criteria are met. We denote the
iteration number as k, which starts with 0 and is incremented by 1 after each iteration.
2-1) Construct weighted linear approximations of the nonlinear function
We first construct a linear approximation around the point x
(k)
i , i.e.,
f(x) ≈ A(k)(i) (x− x(k)i ) + f(x(k)i ) . (15)
Here, A
(k)
(i) ∈ Rm×n describes the “global slope” of the linear approximation around x(k)i .
The key difference of our algorithm compared to others is that we approximate the Jacobian like
matrix A
(k)
(i) collectively using all the function evaluations of f in the previous iteration, i.e.,
A
(k)
(i) = argminA∈Rm×n
N∑
j=1
[
d
(k)
j(i)
∣∣∣∣∣∣f(x(k)j )− {A(x(k)j − x(k)i )+ f(x(k)i )}∣∣∣∣∣∣
2
]2
= argminA∈Rm×n
N∑
j=1
(
d
(k)
j(i)
∣∣∣∣∣∣∆y(k)j(i) −A∆x(k)j(i)∣∣∣∣∣∣
2
)2
(16)
for i = 1, ..., N , where d
(k)
j(i) ≥ 0, j = 1, ..., N are weights. Here, ∆y(k)j(i) = f(x(k)j )− f(x(k)i ) ∈ Rm and
∆x
(k)
j(i) = x
(k)
j − x(k)i ∈ Rn. (Note that ∆y(k)i(i) = 0, ∆x(k)i(i) = 0.)
Also, let
∆Y
(k)
(i) =
[
∆y
(k)
1(i),∆y
(k)
2(i), . . .∆y
(k)
N(i)
]
∈ Rm×N (17)
∆X
(k)
(i) =
[
∆x
(k)
1(i),∆x
(k)
2(i), . . .∆x
(k)
N(i)
]
∈ Rn×N . (18)
Note that f(x
(k)
i ) are always computed at the previous iteration (e.g., as equation (12) when k = 0
and in Step 2-3 when k > 0). Hence, no new evaluation of f is required at this step.
The key idea here is that we weight the information of the function evaluation near x
(k)
i more than
the function evaluation further away. That is to say, d
(k)
j(i) > d
(k)
j′(i) if ||x(k)j − x(k)i || < ||x(k)j′ − x(k)i ||.
More specifically, we obtain matrix A
(k)
(i) row by row by solving the following linear least squares
problem using the CGNR (CGLS) algorithm [4, 13] setting the initial iterate as α = 0. Here, methods
based on the QR decomposition could also be used [4]. However, using the CGNR has the advantage
that it does not break down even though ∆X
(k)T
(i) is rank-deficient[9].
α
(k)
j(i) = argminα∈Rn
∣∣∣∣∣∣D(k)(i) (∆X(k)T(i) α−∆η(k)j(i))∣∣∣∣∣∣
2
(19)
for i = 1, ..., N and j = 1, ...,m, where α
(k)T
j(i) is the j th row of matrix A
(k)
(i) ,
D
(k)
(i) = diag
(
d
(k)
1(i), d
(k)
2(i), ..., d
(k)
N(i)
)
, (20)
and η
(k)
j(i) ∈ RN is the j th column vector of matrix ∆Y (k)T(i) , i.e.,
∆Y
(k)T
(i) =
[
∆η
(k)
1(i),∆η
(k)
2(i), ...,∆η
(k)
m(i)
]
∈ RN×m. (21)
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See Appendix C for the derivation of equation (19).
For our numerical experiments, we have chosen the weights as
d
(k)
j(i) =

(
1∑n
l=1((x
(k)
lj −x
(k)
li )/(x
U
l −xLl ))2
)γ
if j 6= i
0 if j = i
, (22)
where x
(k)
lj , x
U
l , x
L
l are the l th element of the vectors x
(k)
j ,x
U,xL, respectively (l = 1, ..., n), and γ ≥ 0
is a constant. The distance between xi and xj are normalised by the upper and lower bounds of the
initial iterate (i.e., xU and xL). The effect of the weight d
(k)
j(i) is analysed in Appendix D.
2-2) Solve for x that minimizes ||y∗ − (A(k)(i) (x− x(k)i ) + f(x(k)i ))|| 22
We now approximate X(k+1) using the matrices {A(k)(i) }Ni=1 similarly to the Gauss-Newton method
with Tikhonov regularisation (e.g., [8, 4]), i.e.,
x
(k+1)
i = x
(k)
i +
(
A
(k)T
(i) A
(k)
(i) + λ
(k)
i I
)−1
A
(k)T
(i) (y
∗ − y(k)i ) (23)
for i = 1, ..., N,
where y∗ is the set of observations one wishes to fit the nonlinear function f to (cf. (1)), and
y
(k)
i ≡ f(x(k)i ). Here also, we use CGNR to avoid breakdown when A(k)(i) is rank-deficient. The im-
portance of the regularisation can be seen in the numerical experiment presented in Appendix E.
2-3) Update matrices X and Y and vectors r and λ
Evaluate the nonlinear function f for each x
(k+1)
i and store in matrix Y
(k+1) similarly to equation
(12), calculate the residual vector r(k+1) similarly to equation (13).
We now revert to x
(k)
i and increment the regularisation parameter if the residual does not decrease,
i.e.,
if r
(k)
i < r
(k+1)
i or f(x
(k+1)
i ) can not be evaluated, then let
x
(k+1)
i = x
(k)
i (24)
y
(k+1)
i = y
(k)
i (25)
λ
(k+1)
i = 10λ
(k)
i (26)
else decrease the regularisation parameter, i.e.,
λ
(k+1)
i =
1
10
λ
(k)
i , (27)
for each i = 1, , N .
3 Numerical Experiment
To illustrate the advantages of the proposed algorithm, we have conducted numerical experiments.
3.1 Numerical Experiment setup
In this section we specify the detail of thje numerical experiments.
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3.1.1 Mathematical models
For this numerical experiment, we have used the following three published mathematical models of drug con-
centration in the blood of a human body (PBPK model). The time course drug concentration was simulated
from the model, and random noise was added to mimic the observation uncertainties. The simulated drug
concentration was used as the observation, and multiple possible parameters were estimated using CGN and
conventional nonlinear least squares solvers.
Example 1: Multi-dose problem
For this example, we consider the case where three different amounts of the drug is given (low-dose, medium-
dose, and high-dose) orally as pills to a patient. This can be modelled using the same mathematical model
as in the Motivating Example (cf. Appendix A, F, and G). The initial value problem of this mathematical
model can be written as:
du
dt
= g(u, t;x) , (28)
ui(t = 0) = 0 for i = 1, ..., 17, 19, 20 , (29)
u18(t = 0) =
 30000 for low-dose,100000 for medium-dose,
300000 for high-dose.
(30)
In this mathematical model, u1(t) represents the drug concentration in blood at time t. For convenience, we
denote the drug concentration at time t when the low-dose, medium-dose, and high-dose are given as ul1(t;x),
um1 (t;x), and u
h
1(t;x), respectively. Note that the right hand side of the system of ODEs (28) depends on
the parameter vector x. Hence, the solution of the system of ODEs u depends not only on t but also on x.
For this example, we consider the case where the blood sample is taken at t = 2, 3, 4, 6, 8, 12, 24, 36, 48, 72,
so that the nonlinear function f in (1) can be written as
f(x) = [ul1(2;x), u
l
1(3;x), u
l
1(4;x), u
l
1(6;x), u
l
1(8;x), u
l
1(12;x), u
l
1(24;x), u
l
1(36;x),
ul1(48;x), u
l
1(72), u
m
1 (2;x), u
m
1 (3;x), u
m
1 (4;x), u
m
1 (6;x), u
m
1 (8;x), u
m
1 (12;x),
um1 (24;x), u
m
1 (36;x), u
m
1 (48;x), u
m
1 (72), u
h
1(2;x), u
h
1(3;x), u
h
1(4;x), u
h
1(6;x),
uh1(8;x), u
h
1(12;x), u
h
1(24;x), u
h
1(36;x), u
h
1(48;x), u
h
1(72)]
T.
This example is based on [6].
Example 2: intravenous injection and oral administration problem
For this example, we consider the case where the drug is administered via injection into the vein (i.v.) and
the case where the drug is given orally as a pill (p.o.) to a patient. This was modelled using a mathematical
model similar to the Motivating Example. The initial value problem of this mathematical model for i.v.
administration can be written as:
du
dt
= g˜(u, t;x) , (31)
u1(t = 0) =
30.488
0.074 + 10x4
, (32)
ui(t = 0) = 0 for i = 2, 3, ..., 20 , (33)
where x4 is one of the parameters in the parameter vector x. The initial value problem of this mathematical
model for p.o. administration can be written as:
du
dt
= g˜(u, t;x) , (34)
ui(t = 0) = 0 for i = 1, ..., 20 , (35)
u18
(
t =
ex11
2(1 + ex11)
)
= 30.488 , (36)
ui
(
t =
ex11
2(1 + ex11)
)
= 0 for i = 1, ..., 17, 19, 20 , (37)
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where x11 is one of the parameters in the parameter vector x.
ex11
2(1+ex11 ) is the delay in the absorption of
the drug (for example the time it takes from intake in the mouth to pill being dissolved in the stomach).
Similarly to Example 1, the observable quantity, the drug concentration in blood plasma is represented as
u1(t;x). For convenience, we denote the drug concentration at time t when the drug is administrated by
i.v. and p.o. administrations as ui1(t;x) and u
p
1(t;x), respectively. For this example, we consider the case
where the blood sample is taken at t = 0.0833, 0.1667, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8 when the drug is given
as intravenous injection and the blood sample is taken at t = 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 14 when the drug is
given as a pill orally. The nonlinear function f can be written as
f(x) = [ui1(0.0833;x), u
i
1(0.1667;x), u
i
1(0.25;x), u
i
1(0.5;x), u
i
1(0.75;x), u
i
1(1;x),
ui1(1.5;x), u
i
1(2;x), u
i
1(3;x), u
i
1(4;x), u
i
1(6;x), u
i
1(8;x), u
p
1(0.5;x), u
p
1(1;x),
up1(1.5;x), u
p
1(2;x), u
p
1(3;x), u
p
1(4;x), u
p
1(6;x), u
p
1(8;x), u
p
1(12;x), u
p
1(14;x)]
T.
This example is based on [18].
Example 3: drug-drug interaction problem
For this example, we consider the case when a patient takes two different drugs. As it is often stated in
the instruction for the drug, if two drugs are taken together, they can potentially interact inside the body
and can cause an undesirable effect. We model the cases where pitavastatin (for the ease of writing we shall
refer to this drug as Drug A) is taken alone or with cyclosporin A (Drug B). The concentration of Drug A
is modelled using a mathematical model similar to the Motivating Example and Drug B is modelled using a
simplified version of the model. The interaction of Drugs A and B in the liver compartment, when they are
administered at the same time is also modelled.
The initial value problem of the mathematical model for Drug A can be written as
du
dt
= g(u, t;x) (38)
ui(t = 0) = 0 for i = 1, ..., 20 , (39)
u12
(
t =
ex18
2(1 + ex18)
)
= 30.4971 , (40)
ui
(
t =
ex18
2(1 + ex18)
)
= 0 for i = 1, ..., 11, 13, ..., 20 . (41)
The initial value problem of the mathematical model for Drug A administered with Drug B can be written
as:
du
dt
= h(u, t;x) (42)
ui(t = 0) = 0 for i = 1, ..., 33 , (43)
u12
(
t =
ex18
2(1 + ex18)
)
= 30.4971 , (44)
u33
(
t =
ex19
2(1 + ex19)
)
= 2000 , (45)
ui
(
t =
ex18
2(1 + ex18)
)
= 0 for i = 1, ..., 11, 13, .., 33 , (46)
ui
(
t =
ex19
2(1 + ex19)
)
= 0 for i = 1, ..., 32 . (47)
For convenience, we denote the concentration of Drug A at time t when only Drug A is administered as
uA1 (t;x). When both Drugs A and B are administered, we denote the drug concentration of Drug A as
uAB1 (t;x) and the concentration of Drug B as u
AB
21 (t;x). For this example, we consider the case where
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Model structure
Parameters Simulated
to be Estimated Observations
Model 1
Three systems of nonlinear ODEs
11 parameters 30 observations
with 20 variables
Model 2
Two systems of linear ODEs
11 parameters 22 observations
with 20 variables
Model 3
Two systems of nonlinear ODEs
19 parameters 24 observations
with 20 and 33 variables
Table 2: Summary of mathematical description of the PBPK models used for the numerical experiments.
the blood sample is taken at t = 0.5, 1, 1.5, 2, 3, 5, 8, 12, and for the case where both Drugs A and B are
administered, we measure the drug concentration of both drugs. The nonlinear function f can be written as
f(x) = [uA1 (0.5;x), u
A
1 (1;x), u
A
1 (1.5;x), u
A
1 (2;x), u
A
1 (3;x), u
A
1 (5;x), u
A
1 (8;x),
uA1 (12;x), u
AB
1 (0.5;x), u
AB
1 (1;x), u
AB
1 (1.5;x), u
AB
1 (2;x), u
AB
1 (3;x), u
AB
1 (5;x),
uAB1 (8;x), u
AB
1 (12;x), u
AB
21 (0.5;x), u
AB
21 (1;x), u
AB
21 (1.5;x), u
AB
21 (2;x), u
AB
21 (3;x),
uAB21 (5;x), u
AB
21 (8;x), u
AB
21 (12;x)]
T
This example is based on [20].
The mathematical description of each PBPK model used for the numerical experiments is summarised
in Table 1.
3.1.2 Computation environment
All computational experiments were performed using Matlab 2017a on 3.1 GHz Intel Core i5 processors with
MacOS version 10.12.5. The algorithm was written in C++ language and compiled as mex file using clang
version 8.1.0. All results of the numerical experiments were summarised and visualised using ggplot2 version
2.2.1 [17] in R version 3.3.2.
3.1.3 Algorithm parameter setting
The initial set of vectors {x(0)i }Ni=1: We generate the initial set of vectors {x(0)i }Ni=1 uniformly randomly
in the range of the pharmacologically feasible parameter range based on apriori knowledge (e.g., from the
values obtained from the animal experiments or lab experiments).
ODE solver: For Examples 1 and 3 the nonlinear function evaluations require evaluations of stiff systems
of ODEs. We use the ODE15s solver [14] with the default setting to evaluate these ODEs. We observed that
for some set of parameters, the ODE solver can get stuck in an infinite loop. Here, we set the timeout, where
if the ODE evaluation takes longer than 5 seconds, it terminates the evaluation and returns a not-a-number
vector.
Levenberg-Marquardt (LM) method: We compare the proposed method with the widely known
nonlinear least square solver, Levenberg-Marquardt (LM) method [4], that is implemented in the lsqcurvefit
function in Matlab. We use each parameter vector in {x(0)i }Ni=1 as the initial estimate and estimate the
parameter repeatedly for N times to obtain N set of estimated parameter vectors.
We use LM with default setting as well as set ‘FiniteDifferenceStepSize’ to be the square root of the
default accuracy of the ODE solve (e.g., FiniteDifferenceStepSize =
√
AbsTol =
√
10−6). Note that the
FiniteDifferenceStepSize of the default setting is 10−6.
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Cluster Gauss-Newton (CGN) method: We use the following parameters unless stated otherwise:
λinit = 1 (48)
N = 250. (49)
We repeat the iteration for 100 times or until λi > 10
10. As can be seen in Equation (23), x
(k+1)
i ≈ x(k)i for
large λi, so that we can expect very small update in x
(k+1)
i . Hence, in order to mimic the minimum step
size stopping criteria, we stop the update and set x
(k+1)
i = x
(k)
i for i where λi > 10
10.
3.2 Result: Accuracy
One of the advantages of CGN is that it is more robust against local minima of the nonlinear least squares
problem. Hence, we are more likely to obtain the solution of the problem accurately.
From Figures 2-4 we can qualitatively observe that CGN fits the model to the observation at least as
well as LM. Figures 3 and 4 show that LM can suffer more from local convergence depending on the initial
guess of the parameter compared to CGN.
As can be seen in Figure 5, for Example 1 we observe that CGN finds approximately as many accurate
(small SSR) solutions of the nonlinear least squares problem as LM. For Examples 2 and 3, CGN finds more
accurate solutions than LM.
In Figure 5, mostly for LM, we can see the step function like behaviour which indicates that LM started
from some initial iterates have converged to local minima. On the other hand, especially for Example 2 and
3, we observe that CGN successfully avoid these local minima.
In addition, Figure 5 shows that the final solution we obtain from LM can be sensitive not only to the
initial guess but also to the size of the finite difference step if the Jacobian matrix is approximated using
finite difference.
For these examples, we were able to adjust the finite element step-size to the theoretical optimal values, as
we know the accuracy of the ODE evaluations (cf. LM). However, when the nonlinear function is a complete
black box, it would not be possible to adjust the step-size and most likely end up using the default setting
(cf. LM def method). As can be seen in Figure 5, without adjusting the step-size, the number of accurate
solutions found by the conventional method (LM def) method are consistently less than CGN.
3.3 Result: Computational efficiency (number of nonlinear function evalua-
tions)
Another advantage of CGN is the small number of required nonlinear function evaluations. When solving
the nonlinear least squares problem with various initial iterates using conventional methods, it is necessary
to solve the problem for each initial iterates one by one. Hence, it is necessary to obtain Jacobian matrix
for each time. On the other hand, CGN collectively solves for all the initial iterates, and obtain the linear
approximation collectively, resulting in significantly less required number of function evaluations, as can be
seen in Figure 6.
3.4 Result: Application to discontinuous nonlinear functions
Obviously, Jacobian based local optimisation methods cannot solve nonlinear least squares problems if the
nonlinear function is discontinuous. On the other hand, the Cluster Gauss-Newton (CGN) method uses
the linear approximation of the nonlinear function in order to capture the global behaviour of the function.
Hence, it does not require the nonlinear function to be continuous.
For the following numerical experiment, we consider the case where the nonlinear function is not con-
tinuous to show that CGN can solve nonlinear least squares problem that the conventional Jacobian based
method cannot solve. We create such a nonlinear function by rounding the nonlinear function of Example 1
((28)-(30)) to the first decimal place.
11
ll
lll l
l
l l
l
ll
lll l
l
l l
l
ll
lll l
l
l l
l
ll
lll l
l
l l
l
ll
lll l
l
l l
l
ll
lll l
l
l l
l
l
llll l
l
l
l
l
l
llll l
l
l
l
l
l
llll l
l
l
l
l
Low Dose Medium Dose High Dose
CG
N m
ethod
LM
 m
ethod
LM
 D
ef m
ethod
0 20 40 60 0 20 40 60 0 20 40 60
10
1000
10
1000
10
1000
Time
D
ru
g 
Co
nc
en
tra
tio
n 
in
 B
lo
od
Figure 2: Example 1: Plot of the simulation of drug concentration (black solid line) with observations (red
dot). The simulations are based on the set of parameters found by each method whose SSR are within
the 200 best fit (out of 250) for each method. CGN method: Cluster Gauss-Newton method, LM method:
Levenberg-Marquardt method, LM Def method: Levenberg-Marquardt method with default setting.
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Figure 3: Example 2: Plot of the simulation of drug concentration (black solid line) with observations (red
dot). The simulations are based on the set of parameters found by each method whose SSR are within the
200 best fit (out of 250) for each method.
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Figure 4: Example 3: Plot of the simulation of drug concentration (black solid line) with observations (red
dot). The simulations are based on the set of parameters found by each method whose SSR are within the
200 best fit (out of 250) for each method.
As can be seen in Figure 7, the CGN method was able to fit the model appropriately to the observation
while LM was unable to find suitable model parameters.
4 Concluding Remarks
We have proposed the Cluster Gauss-Newton (CGN) method, a new computational method for obtaining
multiple solutions of a nonlinear least squares problem. Considering that our previously developed
Cluster Newton method can only solve an underdetermined system of nonlinear equations, the proposed
algorithm has a significantly broader range of applications for parameter estimation problems.
The development of this algorithm was motivated by the parameter estimation problem that appears
in the field of pharmaceutical drug development. The particular nature of the model, where the model is
over parameterised, and consideration of multiple possible parameters is necessary, motivated us to develop
a new computational method. The fact that our algorithm obtains multiple solutions collectively has made
it significantly more computationally efficient and robust against convergence to local minima, compared to
repeatedly solving the least squares problem using the standard Levenberg-Marquardt method. We have
demonstrated these advantages of the proposed method using three examples that come from the real world
drug development projects. Based on this experience, we have identified many potential use cases of this
algorithm among pharmaceutical scientists, so we have created a graphical user interface based software
which is available at http://www.bluetree.me/CGNmethod_for_PBPKmodels.
By minimising the assumption on the nonlinear function, where it can be a “black box” or even non-
differentiable, we have ensured the ease of use for those who may not have a substantial background in
mathematics or scientific computing. We believe this advantage of the proposed method will be appreciated
by potential users of the algorithm in industry. In this paper, we have used the pharmacokinetics models
as examples. However, as we do not assume any particular form of the nonlinear function, we believe the
proposed method can be used for many other mathematical models in various scientific fields. We note that
there are existing derivative-free methods for nonlinear least-squares problems such as [21, 5]. However, our
CGN is unique in the sense that it was developed to obtain multiple solutions.
Although we have paid significant attention to the usefulness of the algorithm for industrial applications,
the unique mathematical properties such as speed of convergence as well as robustness against converging to
local minima can be of mathematical interest. Further investigations on the theoretical convergence as well
as the refinement of the regularisation strategy of the algorithm are left for future research.
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LM Def method
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Figure 5: Number of solutions found by the various methods for given accuracy threshold (tSSR). Smaller
SSR indicates more accurate solution to the nonlinear-least squares problem. CGN method (solid line):
Cluster Gauss-Newton method, LM method: Levenberg-Marquardt method, LM Def method: Levenberg-
Marquardt method with default setting.
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A Motivating Example
In this appendix, we introduce a motivating example to illustrate how the proposed method can be used
in real life. We consider a fictitious scenario where a newly developed drug is tested for the first time in a
human. Before the drug is given to a human, the biochemical properties of the drug are studied in-test-tube
(in-vitro) and in-animal experiments. However, how the drug behaves in the human body is still uncertain.
Based on the results of in-vitro and in-animal experiments, the team has decided that 100mg is a safe amount
of the drug to be given to a human and the experiment is conducted with a healthy normal volunteer, and the
drug concentration in blood plasma is measured throughout time. Using these measurements, we estimate
the multiple possible model parameters which can be used to simulate various scenarios. The following
workflow can be envisioned:
1: Construct a mathematical model based on the understanding of the physiology and
biochemical properties of the drug.
In this example, we use the model presented in [16]. The mathematical model is depicted in Figure 8, and
it can be written as a system of nonlinear ordinary differential equations with 20 variables. There are two
types of model parameters in this model: physiological parameters and kinetic parameters. Examples of
the physiological parameters are the sizes of the organs or the blood flow rates between the organs. As the
human physiology is well studied and these parameters usually do not depend on the drugs, we can assume
these parameters to be known. The kinetic parameters, such as, how fast the drug gets excreted from the
body or how easily it binds to tissues are the parameters that depend on the drug and usually is not very well
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Figure 6: Reduction of the median of sum of squares residual as the number of function evaluations. As each
function evaluation involves solving a system of ODEs numerically, the computational cost is approximately
proportional to the number of function evaluations. CGN method: Cluster Gauss-Newton method, LM
method: Levenberg-Marquardt method, LM Def method: Levenberg-Marquardt method with default setting.
known. Before the first in-human experiment, the drug development team characterises these parameters
using an organ in test-tubes or by administering the drug to an animal. However, these parameters can differ
from animal to human, so we do not have a very accurate estimate of these parameters. The differences in
these parameters between a human and an animal can be several orders of magnitude. Figure 9 depicts plots
of the drug concentration simulation where the kinetic parameters are sampled within a reasonable range
of the parameters. As can be seen in Figure 9, we cannot obtain any useful information just by randomly
sampling the kinetic parameters from the feasible range.
2: Sample multiple possible model parameter sets that fit the model prediction of the drug
concentration to the observed data from the 100mg experiment. We now use the observed data
from the experiment where 100mg of the drug was given to a human. The red dots in Figure 10 depict the
observed data. The left panel of Figure 10 shows some of the simulation results using the parameter sets of the
initial iterate of CGN. The right panel of Figure 10 shows some of the simulation results after 20 iterations of
CGN. As can be seen in Figure 10, CGN can find multiple sets of parameters that fit the observed data. The
parameter values are depicted in the box plots in Figure 11. As can be seen in Figure 11, after 20 iterations
of CGN, the distribution of some of the parameters shrinks significantly suggesting these parameters can be
identified from the observations while the distribution of some of the parameters are unchanged indicating
that these parameters cannot be identified from the observation. In Figure 12, we have plotted scatter plots
of the parameters found by CGN. As can be seen in Figure 12, even if the parameter cannot be identified
from the observation, some nonlinear relationships can occasionally be identified between the parameters.
B Relation with previous work
We initially proposed the Cluster Newton (CN) method for sampling multiple solutions of a system of
nonlinear equations where the number of unknowns is more than number of observations [1, 2, 7].
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Figure 7: Example 1 when the nonlinear function is rounded to one decimal place: Plot of the simulation
of drug concentration (black solid line) with observations (red dot). The simulations are based on the set
of parameters found by each method whose SSR are within the 200 best fit (out of 250) for each method.
Notice that the simulation result is not smooth representing the fact the u1(t;x) is rounded to the first
decimal place resulting in the nonlinear function f to become discontinuous.
The parameter fitting problems presented in [19, 15, 10] uses CN to fit complex PBPK models to the
drug (and its metabolite) concentration measurements over time. As the drug concentration was measured
repeatedly from the patient, there is a larger number of observations than the number of unknown parameters.
CN assumes an underdetermined problem, where the number of observations is less than the number of
parameters. To use CN, in [19, 15, 10], the authors constructed a summary value called Area Under the
time-concentration Curve (AUC) to reduce the number of observations and fit the model to the summary
value using CN. The AUC is essentially the time integral of the drug concentration from the time drug
is administered to infinity. After finding multiple possible parameters that match the AUC of the model
and the observations, Yoshida et al. and Toshimoto et al. [19, 15] selected the parameter sets that fit the
time-course drug concentrations reasonably well from these parameter sets found using CN. Kim et al. [10]
used a parameter set obtained using CN as the initial iterate for the Levenberg-Marquardt method and fitted
the model to the time-course drug concentration data.
Based on the current use of CN, we have identified two bottlenecks of the workflow employed in [19, 15, 10].
Firstly, CN solves a system of underdetermined system of nonlinear equations. Hence, the model needs
to be constructed in a way that the observation and the model prediction match exactly. Hence, if there
is a model misspecification or significant measurement error that influence the summary values (e.g. AUC)
sufficiently so that there is no model prediction that exactly matches the observation derived summary value,
then CN breaks down.
Secondly, in order to obtain the parameter sets that reasonably fit the original data (e.g., time-course
concentration data), we need to obtain many parameter sets that fit the summary values (e.g., AUC). This
is simply because we need to randomly sample from (number of parameters)-(number of summary values)
dimension space to obtain the desired parameter sets. As a result, [15] had to find 500 000 parameter sets
that fit the summary value (AUC) using CN and then was able to obtain 30 parameter sets that reasonably
fit the original data (time-course drug concentration).
To overcome these bottlenecks, we have suggested these authors to formulate these parameter estimation
problems as nonlinear least squares problem and we have created the Cluster Gauss-Newton method (CGN).
The new method efficiently obtains multiple possible parameters by solving a nonlinear least squares problem
so that the method does not break down even if the model does not exactly match the observation. Also,
the new algorithm does not require the number of observations to be less than the number of parameters
so that there is no need to summarise the observation and can directly use the original observations (e.g.,
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Figure 8: A schematic diagram of a physiologically based pharmacokinetic model. (Arrows represent the
movement of the drug to a different part of the body. Variables ui are the drug concentration or the amount
of the drug in each compartment. The body is divided into Blood, Muscle, Skin, Adipose, Liver and Intestine.
The liver is further divided into ten compartments to model the complex drug behaviour in the liver. The
intestine is divided into four compartments, three transit compartments and one intestine compartment, to
model the time it takes for the drug to reach the intestine.)
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Figure 9: Simulation of the drug concentration in blood plasma using the parameters that are naively
sampled from the range of possible kinetic parameters. Note that these simulations do not give any useful
information.
time-course concentration measurements). As can be seen in Figure 13, the new algorithm enables us to
sample multiple possible parameters significantly more accurately than the approach using CN.
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Figure 10: Plot of the simulation of drug concentration (black solid line) with observations (red dot).
Simulation results are based on the parameters for the initial iterate for CGN and the parameters found after
20 iterations of CGN. In the left panel, the simulation results based on the top 100 sets of the parameters (out
of 1000 parameter sets in the cluster) from the initial cluster are shown. In the right panel, the simulations
results based on the top 100 sets of the parameters (out of 1000 parameter sets in the cluster) after 20
iterations of CGN are shown.
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Figure 11: Box plots of top 100 parameters (parameters whose corresponding SSR is the least 100 within the
cluster) from the initial cluster (left) and the cluster after 20 iterations of CGN (right). Note the distributions
of x5, x8, x9, x10 clearly shrunk after 20 iterations while the distribution of x4 did not change noticeably.
(Box plot: The edges of the boxes are the 75th and 25th percentiles. The line in the box is the median, and
the whiskers extend to the largest and the smallest value within the 1.5 times the inter-quartile range. Dots
are the outliers outside the whiskers.)
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Figure 12: Scatter plots of parameters. As can be seen in this example, we can find parameter-parameter
correlations of some of the parameters found by CGN.
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Figure 13: Comparison of the accuracy of the model fit of the Motivating Example (cf. Appendix A)
using the approach employed in [19, 15] using the Cluster Newton (CN) method and the proposed Cluster
Gauss-Newton (CGN) method.
C Derivation of equation (19)
From equation (16) we have
A
(k)
(i) = argminA∈Rm×n
N∑
j=1
(
d
(k)
j(i)
∣∣∣∣∣∣∆y(k)j(i) −A∆x(k)j(i)∣∣∣∣∣∣
2
)2
, (50)
= argminA∈Rm×n
N∑
j=1
∣∣∣∣∣∣d(k)j(i) (A∆x(k)j(i) −∆y(k)j(i))∣∣∣∣∣∣ 2
2
,
= argminA∈Rm×n
∣∣∣∣∣∣(A∆X(k)(i) −∆Y (k)(i) )D(k)(i) ∣∣∣∣∣∣ 2
F
,
= argminA∈Rm×n
∣∣∣∣∣∣D(k)(i) (∆X(k)T(i) AT −∆Y (k)T(i) )∣∣∣∣∣∣ 2
F
,
where ||B||F =
(∑m
i=1
∑n
j=1 b
2
ij
) 1
2
is the Frobenius norm of the matrix B = (bij) ∈ Rm×n.
LetA
(k)T
(i) =
[
α
(k)
1(i), ...,α
(k)
m(i)
]
∈ Rn×m, whereα(k)j(i) ∈ Rn for j = 1, ...,m, and ∆Y (k)T(i) =
[
∆η
(k)
1(i),∆η
(k)
2(i), ...,∆η
(k)
m(i)
]
∈
RN×m, where ∆η(k)j(i) ∈ RN , for j = 1, ...,m. Then, equation (50) is equivalent to
α
(k)
j(i) = argminα∈Rn
∣∣∣∣∣∣D(k)(i) (∆X(k)T(i) α−∆η(k)j(i))∣∣∣∣∣∣
2
j = 1, ...,m, (51)
which is equivalent to equation (19).
Note that equation (50) is equivalent to the normal equations
∆X
(k)
(i) D
(k)2
(i) ∆X
(k)T
(i) A
(k)T
(i) = ∆X
(k)
(i) D
(k)2
(i) ∆Y
(k)T
(i) , (52)
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Figure 14: Number of solutions found for given accuracy threshold (tSSR) using various weights for the
linear approximation (i.e., various γ). Smaller SSR indicates more accurate solution to the nonlinear-least
squares problem.
and equation (51) is equivalent to the normal equations
∆X
(k)
(i) D
(k)2
(i) ∆X
(k)T
(i) α
(k)
j(i) = ∆X
(k)
(i) D
(k)2
(i) ∆η
(k)
j(i) j = 1, ...,m. (53)
D Numerical experiments on the influence of the weight of the
linear approximation
To illustrate the influence of the weight d
(k)
j(i) for the weighted linear approximation in 2-1 of the algorithm, we
conducted numerical experiments using Example 1. For this numerical experiment, we varied the parameter
γ ≥ 0 in equation (22):
d
(k)
j(i) =

(
1∑n
l=1((x
(k)
lj −x
(k)
li )/(x
U
l −xLl ))2
)γ
if j 6= i
0 if j = i
. (54)
In Figure 14, we show the number of solutions found by CGN for given accuracy threshold. In Figure 15,
we show the convergence plot of SSR. As can be seen from Figures 14 and 15, the weight for the linear
approximation improves the accuracy and the speed of CGN. Note that γ = 0, which corresponds to giving
equal weights to all the cluster points is not optimal. In this example, γ = 2 gave the best result.
E Numerical experiments on the influence of the regularisation
To illustrate the necessity and the influence of the regularisation in 2-2 of the algorithm, we conducted
numerical experiments using Example 1. We varied the initial value of the regularisation coefficient λinit and
tested CGN. In Figure 16, we show the number of solutions found by CGN for given accuracy threshold. In
Figure 17, we show the convergence of SSR. As can be seen from Figures 16 and 17, the regularisation is
necessary for CGN to perform well. For this example, λinit = 0.1 gave the best result.
F ODE expressions of the PBPK model used as the motivating
example
In this subsection we explicitly write out the mathematical model used in the motivating example in Ap-
pendix A as a system of ODEs. The other PBPK models used in this paper can be similarly written as a
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Figure 15: Reduction of the median of sum of squares residual as the number of function evaluations with
various weights for the linear approximation (i.e., various γ). As each function evaluation involves solving a
system of ODEs numerically, the computational cost is approximately proportional to the number of function
evaluations.
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Figure 16: Number of solutions found for given accuracy threshold (tSSR) using various initial lambda
(λinit). Smaller SSR indicates more accurate solution to the nonlinear-least squares problem.
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Figure 17: Reduction of the median of sum of squares residual as the number of function evaluations with
various initial lambda (λinit). As each function evaluation involves solving a system of ODEs numerically,
the computational cost is approximately proportional to the number of function evaluations.
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system of ODEs. For the model parameters appearing in these ODEs, we follow the usual notations used in
pharmacokinetics and we will provide brief descriptions of these parameters. For more detailed description
of these parameters, we refer the reader to the standard textbooks in pharmacokinetics (e.g., [12]).
ODE for the blood compartment
du1
dt
=
Qh(u13 − u1)− CLru1 −Qm(u1 − u2KpmKpscalar )−Qs(u1 − u3KpsKpscalar )
Vb
−
Qa(u1 − u4KpaKpscalar )
Vb
Qh is the blood flow rate through the liver. The unit is typically L/hr.
CLr is the rate of the drug being excreted as urine. The unit is typically L/hr.
Vb is the volume of the blood compartment. The unit is typically L.
Qm, Qs, Qa are the blood flow rates to muscle, skin, and adipose, respectively. The unit is typically L/hr.
Vm, Vs, Va are the volumes of muscle, skin, and adipose compartments, respectively. The unit is typically L.
Kpm,Kps,Kpa are the partition coefficients of the drug for the muscle, skin and adipose, respectively.
The partition coefficient is the ratio between the drug concentration in the blood plasma and the tissue
at equilibrium when the tissue is in contact with the blood. We usually assume that these values can be
measured by in-vitro experiments. Hence, they are usually fixed parameters in the model.
Kpscalar is a scaling factor for the partitioning.
ODE for the muscle compartment
du2
dt
=
Qm
Vm
(
u1 − 1
KpmKpscalar
u2
)
(55)
ODE for the skin compartment
du3
dt
=
Qs
Vs
(
u1 − 1
KpsKpscalar
u3
)
(56)
ODE for the adipose (fat) compartment
du4
dt
=
Qa
Va
(
u1 − 1
KpaKpscalar
u4
)
(57)
ODEs for the liver compartments
For a compartment representing the blood vessel in the liver (Liver Sinusoid 1)
du5
dt
= −
Vmaxuptake
Kmuptake+u5
+ fb PSdif
Vhc
u5 +
fh PSdif
Vhc
u6 +
Qh(u1 − u5) + ka u18
Vhc
5
(58)
ka is the rate of the drug being absorbed from the intestines and transported to the liver through the portal
vein. The unit is typically L/hr.
Vhc is the volume of the blood in blood vessel.
PSdiff is the diffusion constant between the liver sinusoid compartment and the hepatocyte compartment.
fb is the ratio of the drug that is not bound to the protein in blood in the blood vessel in the liver.
fh is the ratio of the drug that is not bound to the protein in the liver cells. Only the portion of the drug
that is not bound to the protein can permeate in and out of the liver cells.
For compartments representing the blood vessel in the liver (Liver Sinusoid 2, 3, 4, 5)
du7+2i
dt
= −
Vmaxuptake
Kmuptake+u7+2i
+ fb PSdif
Vhc
u7+2i +
fh PSdif
Vhc
u8+2i +
Qh(u5+2i − u7+2i)
Vhc
5
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for i = 0, 1, 2, 3.
Vmaxuptake and Kmuptake are constants for the Michaelis-Menten kinetics where the active uptake of the
drug from the blood to the liver cells by membrane transport protein (also known as “transporter”).
Compartments representing liver cells (Hepatocyte 1, 2, 3, 4, 5)
du6+2i
dt
=
Vmaxuptake
Kmuptake+u5+2i
+ fb PSdif
Vhe
u5+2i − fh(PSdif + (CLmet + CLbile))
Vhe
u6+2i
for i = 0, 1, 2, 3, 4.
Vhe is the volume of liver cells.
ODE for the transit compartment 1
du15
dt
= fh CLbile
u6 + u8 + u10 + u12 + u14
5
− kbile u15 (59)
u15 is the amount of the drug in the transit compartment 1. Transit compartment can be thought of as
a fictitious compartment that introduces the delay of the drug delivery to to the intestines. CLmet is a
clearance (speed that drug is cleared out) due to the metabolisation of the drug of the subject. The unit is
typically L/hr.
CLbile is a clearance due to the biliary excretion of the drug of the subject. The unit is typically L/hr.
kbile is a diffusion coefficient between the transit compartments. The unit is typically 1/hr.
fh is the fraction of the drug cleared by liver, it is typically unit-less.
ODE for the transit compartment 2
du16
dt
= kbile (u15 − u16) (60)
u16 is the amount of the drug in the transit compartment 2. kbile is a diffusion constant where the drug is
diffused into bile, the unit is typically 1/hr.
ODE for the transit compartment 3
du17
dt
= kbile (u16 − u17) (61)
u17 is the amount of the drug in the transit compartment 3.
ODE for the intestine compartment
du18
dt
= kbile u17 − ka
FaFg
u18 (62)
u18 is the amount of the drug in the intestine. FaFg is the fraction of the drug that gets absorbed by the
intestines.
G Re-parameterisation
For the mathematical model we have introduced in Appendix F, some of the parameters may be known for
the drug of interest. For the motivating example presented in Appendix A, we have assumed the following
parameters to be known:
CLr = 0, FaFg = 0.55, Kpa = 0.086, Kpm = 0.113 (63)
Kps = 0.478, Qa = 15.61, Qh = 86.94, Qm = 44.94 (64)
Qs = 17.99, Va = 10.01, Vhc = 1.218, Vhe = 0.469 (65)
Vm = 30.03, Vs = 7.77, fb = 0.00617, fh = 0.012 (66)
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Also, most of the parameters have known physiologically or chemically possible range (e.g., clearances
cannot be negative). Thus for those parameters, we re-parameterise to impose known constraints. For the
motivating example presented in Appendix A, we have re-parameterised as in the followings:
CLbile = 10
x1 , CLmet = 10
x2 , Kmuptake = 10
x3 , (67)
KpScalar =
ex4
1 + ex4
PSdif = 10x5 , V b = 10x6 , (68)
V maxuptake = 10
x7 , ka = 10x8 kbile = 10
x9 . (69)
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